论文部分内容阅读
中新社天津2月6日电南开大学6日披露,一项中美科学家合作研究的成果,成功揭示了在肺纤维化发生发展过程中新的起重要作用的靶点蛋白FSTL1及相关调控通路,提示了其潜在的临床应用价值,并试制出能够有效抑制肺纤维化发展的潜在药物。该成果由南开大学生命科学学院·药物化学生物学国家重点实验室宁文教授课题组和美国Cedars-Sinai医学中心蒋典华教授合作研究,成果论文已被国际著名医学期刊《实验医学杂志》在线发表。脏器纤维化疾病是当前国际医学领域研究的重大难
China news agency, Tianjin, February 6 Nankai University disclosed on the 6th, a Sino-U.S. Collaborative research scientists successfully revealed the occurrence and development of pulmonary fibrosis in the new play an important role in the target protein FSTL1 and related regulatory pathway , Suggesting its potential value of clinical application, and try out a potential drug that can effectively inhibit the development of pulmonary fibrosis. This achievement was jointly researched by Professor NING Wen from the State Key Laboratory of Medicinal Chemistry Biology, School of Life Sciences, Nankai University and Professor Jiang Dianhua from Cedars-Sinai Medical Center, USA. The dissertation has been published online in the journal The Journal of Experimental Medicine. Organ fibrosis is a major challenge in the current international medical research